Intra-Cellular Therapies (ITCI) PT Raised to $38 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Intra-Cellular Therapies (ITCI) PT Raised to $28 at SunTrust Robinson Humphrey; 'Adding Back Bipolar Depression'
March 2, 2018 9:03 AM ESTSunTrust Robinson Humphrey raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $28.00 (from $22.00) while maintaining a Buy rating.
Analyst Edward Nash commented, "Intra-Cellular will have a pre-NDA meeting with the FDA in 1Q18 for lumateperone for schizophrenia. Company expects to file NDA for... More
Intra-Cellular Therapies (ITCI) PT Raised to $28 at Cowen
March 2, 2018 1:23 AM ESTCowen raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $28.00 (from $27.00) while maintaining a Outperform rating.
... More